2028年までのアジア太平洋心血管代謝疾患市場予測 - 新型コロナウイルス感染症の影響と地域分析（心血管疾患（CVD）、2型糖尿病、高血圧、肥満）、治療法（ACE阻害剤、利尿薬、グルコファージなど）、用量別（錠剤、注射）、投与経路（経口、静脈内）、エンドユーザー（病院、診療所、在宅医療環境）、流通チャネル（病院の薬局、小売薬局、オンライン薬局）
市場紹介
心臓代謝疾患は、以下のような一連の異常と症状を特徴としています。個人が心血管疾患を発症するリスク。高血圧、肥満、インスリン抵抗性、脂質異常症、コレステロールプロファイル（LDL）低下、耐糖能などが症状の一部です。心メタボリックシンドロームに罹患している人は、2 型糖尿病、脳卒中、冠動脈疾患 (CAD)、心血管疾患 (CVD) など、他のいくつかの生命を脅かす病気にかかりやすいです。
さらに、心臓代謝性疾患の有病率の増加により、予測期間中の市場の成長が促進されると予想されます。しかし、低中所得国 (LMIC) における CVD の過小診断により、アジア太平洋地域の心臓代謝性疾患市場の成長が制限されています。
サプライチェーンの混乱と医療の大量需要により、新型コロナウイルス感染症の効率的な治療法により、アジア太平洋地域の医療研究業界は重大な状況に陥っています。このパンデミックの蔓延を制御するために禁止的な措置が講じられています。新型コロナウイルス感染症のパンデミックは、アジア太平洋地域の経済に広く影響を及ぼしています。インド（31,769,132人）、日本（956,407人）、中国（93,289人）、韓国（203,926人）などの国々がパンデミックによる悪影響を受けました。社会経済は深刻な影響を受け、マイナスのインフレ、GDP、地域の失業率の上昇が見られました。近年、日本では高血圧と肥満を併発する患者が増加しています。これらの患者は、新型コロナウイルス感染症による重症化のリスクが非常に高いため、慎重な観察と集中的な治療が必要です。高血圧と同様に、肥満の定義は研究や国によって一定ではなく、考慮が必要です。ただし、新型コロナウイルス感染症 (COVID-19) に対する CCB の治療メカニズムは、まださらなる調査とランダム化対照臨床試験を待っていることに留意することが重要です。
市場の概要とダイナミクス
アジア太平洋地域の心臓代謝疾患市場は、2021年の210億9,130万米ドルから2028年までに289億5,320万米ドルに達すると予測されています。 2021 年から 2028 年までに 4.6% の CAGR で成長すると予想されています。心臓代謝性疾患 (CMD) は、世界中で主な死因の 1 つです。これらの病気は主に、不健康なライフスタイル、運動不足、喫煙、不健康な食生活によって引き起こされます。 CMD には、心血管疾患 (CVD)、糖尿病、および慢性腎不全が含まれます。ほとんどの心血管疾患は、喫煙、不健康な食事の選択、肥満、運動不足、アルコール摂取などの行動危険因子に対処することで予防できます。糖尿病は、機能的な治療法のない、生命を脅かす慢性疾患の 1 つです。それはさまざまな合併症を引き起こし、早期死亡の全体的なリスクを高めます。心臓発作、脳卒中、腎不全、下肢切断、視力喪失、神経損傷は、糖尿病に関連する主な合併症です。喫煙、運動不足、アルコール摂取、不健康な食生活の増加により、1 つ以上の CMD を患う人の数が増加しています。肥満の有病率の増加により、CMD に苦しむ患者層も増加しています。 CMD の有病率の急速な上昇に伴い、適切な心臓代謝疾患治療の必要性が急増し、その結果、アジア太平洋地域の心臓代謝疾患市場は大幅に成長しました。
< u>主要市場セグメント
種類の観点から見ると、2020 年のアジア太平洋心臓代謝疾患市場で最大のシェアを占めたのは心血管疾患セグメントでした。治療に関しては、ACE阻害剤セグメントが2020年のアジア太平洋心筋代謝疾患市場で最大のシェアを占め、用量に関しては錠剤セグメントが2020年のアジア太平洋心筋代謝疾患市場で最大のシェアを占めました。投与経路別では、経口セグメントが2020年のアジア太平洋心筋代謝疾患市場で最大のシェアを占めました。エンドユーザーに関しては、病院セグメントが2020年のアジア太平洋心筋代謝疾患市場で最大のシェアを占めました。流通チャネルでは、病院薬局部門 が 2020 年に最大の市場シェアを保持しました。
リストされている主要な供給元と企業 u>
アジア太平洋地域の心臓代謝疾患市場に関するこのレポートを作成するために参照したいくつかの主要な一次および二次情報源は、企業の Web サイト、年次報告書、財務報告書です。 、国家政府文書、統計データベースなど。このレポートに記載されている主要企業は、Eli Lilly and Company.、Bayer AG、Novartis AG、Boehringer Ingelheim International Gmbh、Novo Nordisk A/S、AstraZeneca、Cardax Inc.、興和株式会社です。
購入理由レポート
- アジア太平洋地域の心臓代謝疾患市場の状況を理解し、高い収益を保証できる市場セグメントを特定する
- 絶えず変化する市場の状況を理解し、今後も継続する競争で優位に立つ
- 最も売上が見込まれるセグメントを特定することにより、アジア太平洋地域の心臓代謝疾患市場における合併・買収および提携取引を効率的に計画するため
- さまざまなセグメントの市場パフォーマンスの知覚的かつ包括的な分析に基づいて、知識に基づいたビジネス上の意思決定を行うため
- アジア太平洋地域の市場収益予測を取得するため2021 ～ 2028 年のさまざまなセグメントに基づく心臓代謝疾患市場
アジア太平洋心臓代謝疾患市場セグメンテーション
種類タイプ
- 心血管疾患 (CVD)
- 2 型糖尿病
- 高血圧
- 肥満
治療別
- ACE 阻害剤
- 利尿薬
- グルコファージ
- その他
用量別
- タブレット
- 注射
投与経路別
- 経口
- 静脈内
エンドユーザーによる >
- 病院
- クリニック
- 在宅医療設定 ;
販売チャネル別
- 病院薬局
- 小売薬局
- オンライン薬局
>国別
- アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- アジア太平洋地域のその他の地域
記載されている企業
- イーライ リリー アンド カンパニー。
- バイエル AG
- ノバルティス AG ;
- ベーリンガー インゲルハイム インターナショナル Gmbh
- ノボ ノルディスク A/S
- アストラゼネカ
- 興和株式会社
- カーダックス株式会社
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.7 Asia Pacific Cardiometabolic Diseases market – By Country
2. Asia Pacific Cardiometabolic Diseases Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Cardiometabolic Diseases Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinions
5. Asia Pacific Cardiometabolic Diseases Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increasing Prevalence of Cardiometabolic Diseases
5.1.2 Innovation in Cardiometabolic Diseases Therapeutics
5.2 Market Restraints
5.2.1 Underdiagnosis of CVDs in Low- and Middle-Income Countries (LMICs)
5.3 Market Opportunities
5.3.1 Technological Advancements in CMD Diagnosis
5.4 Future Trends
5.4.1 Personalized Treatment for CMDs
5.5 Impact Analysis
6. Asia Pacific Cardiometabolic Diseases Market – Regional Analysis
6.1 Asia Pacific Cardiometabolic Diseases Market Revenue Forecast And Analysis
7. Asia Pacific Cardiometabolic Diseases Market Analysis – By Type
7.1 Overview
7.2 Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
7.3 Cardiovascular Disease (CVD)
7.3.1 Overview
7.3.2 Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Hypertension
7.4.1 Overview
7.4.2 Hypertension: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Type 2 Diabetes
7.5.1 Overview
7.5.2 Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Obesity
7.6.1 Overview
7.6.2 Obesity: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8. Asia Pacific Cardiometabolic Diseases Market Analysis – By Treatment
8.1 Overview
8.2 Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
8.3 ACE inhibitors
8.3.1 Overview
8.3.2 ACE: Cardiometabolic Diseases Inhibitors Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Diuretics
8.4.1 Overview
8.4.2 Diuretics: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Glucophage
8.5.1 Overview
8.5.2 Glucophage: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
8.6 Others
8.6.1 Overview
8.6.2 Others: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9. Asia Pacific Cardiometabolic Diseases Market Analysis – By Dosage
9.1 Overview
9.2 Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
9.3 Tablet
9.3.1 Overview
9.3.2 Tablet: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
9.4 Injection
9.4.1 Overview
9.4.2 Injection: Cardiometabolic Diseases Market Revenue and Forecast to 2028 (US$ Mn)
10. Asia Pacific Cardiometabolic Diseases Market Analysis – By Route of Administration
10.1 Overview
10.2 Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
10.3 Oral
10.3.1 Overview
10.3.2 Oral Market Revenue and Forecast to 2028 (US$ Mn)
10.4 Intravenous
10.4.1 Overview
10.4.2 Intravenous Market Revenue and Forecast to 2028 (US$ Mn)
11. Asia Pacific Cardiometabolic Diseases Market Analysis – By End User
11.1 Overview
11.2 Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
11.3 Clinic
11.3.1 Overview
11.3.2 Clinic Market Revenue and Forecast to 2028 (US$ Mn)
11.4 Hospital
11.4.1 Overview
11.4.2 Hospital Market Revenue and Forecast to 2028 (US$ Mn)
11.5 Homecare Settings
11.5.1 Overview
11.5.2 Homecare Settings Market Revenue and Forecast to 2028 (US$ Mn)
12. Asia Pacific Cardiometabolic Diseases Market Analysis – By Distribution Channel
12.1 Overview
12.2 Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
12.3 Hospital Pharmacy
12.3.1 Overview
12.3.2 Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.4 Retail Pharmacy
12.4.1 Overview
12.4.2 Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
12.5 Online Pharmacy
12.5.1 Overview
12.5.2 Online Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)
13. Asia Pacific Cardiometabolic Diseases Market – Geographic Analysis
13.1 Asia Pacific: Cardiometabolic Diseases Market
13.1.1 Overview
13.1.2 Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.3 Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.4 Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.5 Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.6 Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.7 Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.8 Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.9 Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
13.1.9.1 China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.9.1.1 China: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.10 China: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.11 China: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.12 China: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.13 China: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.14 China: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.15 China: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.15.1 Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.15.1.1 Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.16 Japan: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.17 Japan: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.18 Japan: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.19 Japan: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.20 Japan: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.21 Japan: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.21.1 India: Cardiometabolic Diseases Market - Revenue and Forecasts to 2028 (USD Million)
13.1.21.1.1 India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.22 India: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.23 India: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.24 India: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.25 India: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.26 India: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.27 India: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.27.1 South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.27.1.1 South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.28 South Korea: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.29 South Korea: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.30 South Korea: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.31 South Korea: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.32 South Korea: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.33 South Korea: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.33.1 Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.33.1.1 Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.34 Australia: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.35 Australia: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.36 Australia: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.37 Australia: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.38 Australia: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.39 Australia: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
13.1.39.1 Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.39.1.1 Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
13.1.40 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
13.1.41 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
13.1.42 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
13.1.43 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
13.1.44 Rest of Asia Pacific: Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
13.1.45 Rest of Asia Pacific: Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
14. Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market
14.1 Asia Pacific: Impact Assessment of COVID-19 Pandemic
15. Asia Pacific Cardiometabolic Diseases Market – Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Cardiometabolic Diseases Market (%)
15.3 Organic Developments
15.3.1 Overview
15.4 Inorganic Developments
15.4.1 Overview
16. Company Profiles
16.1 Eli Lilly and Company.
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
16.2 Bayer AG
16.2.1 Key Facts
16.2.2 Business Description
16.2.3 Products and Services
16.2.4 Financial Overview
16.2.5 SWOT Analysis
16.2.6 Key Developments
16.3 Novartis AG
16.3.1 Key Facts
16.3.2 Business Description
16.3.3 Products and Services
16.3.4 Financial Overview
16.3.5 SWOT Analysis
16.3.6 Key Developments
16.4 Boehringer Ingelheim International GmbH
16.4.1 Key Facts
16.4.2 Business Description
16.4.3 Products and Services
16.4.4 Financial Overview
16.4.5 SWOT Analysis
16.4.6 Key Developments
16.5 Novo Nordisk A/S
16.5.1 Key Facts
16.5.2 Business Description
16.5.3 Products and Services
16.5.4 Financial Overview
16.5.5 SWOT Analysis
16.5.6 Key Developments
16.6 AstraZeneca
16.6.1 Key Facts
16.6.2 Business Description
16.6.3 Products and Services
16.6.4 Financial Overview
16.6.5 SWOT Analysis
16.6.6 Key Developments
16.7 Cardax, Inc.
16.7.1 Key Facts
16.7.2 Business Description
16.7.3 Products and Services
16.7.4 Financial Overview
16.7.5 SWOT Analysis
16.7.6 Key Developments
16.8 Kowa Company, Ltd.
16.8.1 Key Facts
16.8.2 Business Description
16.8.3 Products and Services
16.8.4 Financial Overview
16.8.5 SWOT Analysis
16.8.6 Key Developments
17. Appendix
17.1 About The Insight Partners
17.2 Glossary of Terms
LIST OF TABLES
Table 1. Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 2. Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 3. Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 4. Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 5. Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 6. Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 7. China Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 8. China Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 9. China Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 10. China Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 11. China Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 12. China Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 13. Japan Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 14. Japan Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 15. Japan Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 16. Japan Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 17. Japan Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 18. Japan Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 19. India Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 20. India Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 21. India Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 22. India Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 23. India Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 24. India Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 25. South Korea Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 26. South Korea Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 27. South Korea Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 28. South Korea Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 29. South Korea Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 30. South Korea Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 31. Australia Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 32. Australia Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 33. Australia Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 34. Australia Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 35. Australia Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 36. Australia Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 37. Rest of Asia Pacific Cardiometabolic Diseases Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 38. Rest of Asia Pacific Cardiometabolic Diseases Market, by Treatment – Revenue and Forecast to 2028 (USD Million)
Table 39. Rest of Asia Pacific Cardiometabolic Diseases Market, by Dosage – Revenue and Forecast to 2028 (USD Million)
Table 40. Rest of Asia Pacific Cardiometabolic Diseases Market, by Route of Administration – Revenue and Forecast to 2028 (USD Million)
Table 41. Rest of Asia Pacific Cardiometabolic Diseases Market, by End Users – Revenue and Forecast to 2028 (USD Million)
Table 42. Rest of Asia Pacific Cardiometabolic Diseases Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 43. Organic Developments in the Cardiometabolic Diseases Market
Table 44. Inorganic Developments in the Cardiometabolic Diseases Market
Table 45. Glossary of Terms, Asia Pacific Cardiometabolic Diseases Market
LIST OF FIGURES
Figure 1. Asia Pacific Cardiometabolic Diseases Market Segmentation
Figure 2. Asia Pacific Cardiometabolic Diseases Market Overview
Figure 3. Cardiovascular Disease (CVD) Segment Held Largest Share of Type of Asia Pacific Cardiometabolic Diseases Market
Figure 4. Asia Pacific Cardiometabolic Diseases Market – Leading Country Markets (US$ Million)
Figure 5. Asia Pacific Cardiometabolic Diseases Market, Industry Landscape
Figure 6. Asia Pacific PEST Analysis
Figure 7. Asia Pacific Cardiometabolic Diseases Market Impact Analysis of Drivers and Restraints
Figure 8. Asia Pacific Cardiometabolic Diseases Market – Revenue Forecast And Analysis – 2020- 2028
Figure 9. Cardiometabolic Diseases Market Revenue Share, by Type (2020 and 2028)
Figure 10. Cardiovascular Disease (CVD): Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Hypertension: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Type 2 Diabetes: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Obesity: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Cardiometabolic Diseases Market Revenue Share, by Treatment (2020 and 2028)
Figure 15. ACE inhibitors: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Diuretics: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. Glucophage: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 18. Others: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 19. Cardiometabolic Diseases Market Revenue Share, by Dosage (2020 and 2028)
Figure 20. Tablet: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 21. Injection: Cardiometabolic Diseases Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 22. Cardiometabolic Diseases Market Share by Route of Administration 2021 & 2028 (%)
Figure 23. Oral Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 24. Intravenous Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 25. Cardiometabolic Diseases Market Share by End Users 2020 & 2028 (%)
Figure 26. Clinic Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. Hospital Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 28. Homecare Settings Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Cardiometabolic Diseases Market Share by Distribution Channel 2020 & 2028 (%)
Figure 30. Hospital Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 31. Retail Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 32. Online Pharmacy Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 33. Asia Pacific: Cardiometabolic Diseases Market, by Key Country – Revenue (2021) (USD Million)
Figure 34. Asia Pacific Cardiometabolic Diseases Market Revenue and Forecast to 2028 (USD Million)
Figure 35. Asia Pacific: Cardiometabolic Diseases Market, by Country, 2021 & 2028 (%)
Figure 36. China Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 37. Japan: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. India: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 39. South Korea: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 40. Australia: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 41. Rest of Asia Pacific: Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (USD Million)
Figure 42. Impact of COVID-19 Pandemic on Asia Pacific Cardiometabolic Diseases Market
Figure 43. Growth Strategies in the Cardiometabolic Diseases Market (%)
- Eli Lilly and Company.
- Bayer AG
- Novartis AG
- Boehringer Ingelheim International Gmbh
- Novo Nordisk A/S
- AstraZeneca
- Kowa Company, Ltd.
- Cardax, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific cardiometabolic diseases market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific cardiometabolic diseases market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.